OREANDA-NEWS. Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announced that the FDA has approved two new product claims for the octyl formulation product, LiquiBand Exceed™ giving it a competitive advantage in the topical skin adhesive market. 

These claims will allow AMS and partners to differentiate LiquiBand Exceed™ around wound coverage, yield and reuse, providing clinicians with the ability to increase the usage of a single applicator, saving time and cost.

The two new claims include the use of a single device to cover wounds of up to 30cm, as well as a single device being suitable for intraoperative reuse for up to 90 minutes on a single patient. Both claims are unique FDA approved claims for the US Topical Skin Adhesive Market. 

Following testing, LiquiBand® Exceed™ was found to deliver best in class yield to support coverage up to 30cm of wound length1, twice the amount advertised by market leading topical skin adhesive products2.  Due to the proprietary LiquiBand Exceed™ formula, the adhesive polymerises via skin contact using naturally occurring skin moisture meaning that the applicator device does not dry out.  In-vitro testing proved the device could continually express glue in intervals for up to 90 minutes after device activation.1 

Chris Meredith, Chief Executive Officer of AMS, commented: "LiquiBand Exceed™ has been an excellent addition to our LiquiBand® topical skin adhesive portfolio demonstrating encouraging initial uptake since its launch this year.  These extended US product claims will help us to continue to provide a superior product for clinicians and a versatile solution for healthcare providers in this key market, in which we are focused on growing our market share."